Home » Posts tagged 'Investors'
Tag Archives: Investors
ECR Minerals #ECR – Adam Jones and Alan Green talk through the upcoming Blue Moon Drilling Campaign
Adam Jones and Alan Green discuss the upcoming Blue Moon drilling campaign. We discuss the intriguing and unique style of mineralisation at Blue Moon, and the impressive grades and widths from the previous 2019 campaign assay results. Adam explains the previous soil geochemistry work undertaken at Blue Moon prior to the previous drilling campaign, before we discuss the upcoming campaign in a few weeks, with a four initial drill holes planned using ECR’s own MIDAS drill rig.
UK Investor Magazine Podcast – Moonpig, B&M European, and oil with Alan Green
#ORPH Open Orphan – Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee.
Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding a number of senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.
Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company’s healthcare practice. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.
Martin holds a BSc in Genetics and has completed a range of post graduate management courses.
Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “I am pleased to welcome Martin to the Board of Open Orphan. Martin has extensive corporate development experience in the CRO, healthcare and pharmaceutical sectors and held a number of senior roles in healthcare AI businesses. I look forward to working closely with Martin as we drive further growth across the business.”
Martin Gouldstone, Non-Executive Director, said: “I am delighted to join the Board of Open Orphan at what is an exciting time for the Company and the infectious disease market as it continues to grow significantly post pandemic. I am delighted to bring my previous three decades of experience in the CRO, healthcare and pharmaceutical industry to the Company as it continues to build and expand on partnerships with leading global biopharma companies.”
Regulatory Disclosures
Save for the information set out above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Mr Martin John Gouldstone, aged 55, Martin does not hold an interest in the Company’s share capital.
|
Current Directorships |
Past Directorships |
|
Novara Therapeutics Limited |
n.a. |
|
Orthopaedic Research UK |
|
|
Sempiternum Ltd |
|
For further information please contact:
|
Open Orphan plc |
+44 20 7756 1300 |
||
|
Yamin ‘Mo’ Khan, Chief Executive Officer |
|||
|
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
|
Ben Cryer / Edward Mansfield / Phil Walker / Will King |
|||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson / Richard Chambers |
|||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|||
|
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / |
||
#KAV Kavango Resources – IOCG Presentation
Botswana focussed metals exploration company Kavango Resources plc (LSE:KAV) is pleased to announce the Company will host an online shareholder event to present the Iron Oxide Copper-Gold (“IOCG”) exploration model for the Great Red Spot.
The Great Red Spot (the “GRS”) is in the northern section of the Kalahari Suture Zone Project. It has been recognised as a large-scale exploration target for major metal and mineral deposits since the mid-1970s. However, technology has only advanced sufficiently in recent years to allow effective exploration.
Kavango has been conducting exploration over this 5km x 8km magnetic body since 2018. Following six months of additional field exploration and detailed desktop analysis, the Company announced the IOCG target on 07 May 2022. A full description of the IOCG target can be read in the announcement (link below):
IOCG systems can host highly valuable copper, gold and uranium ores. The large size and relatively simple metallurgy can produce extremely profitable mines.
IOCG deposits are an alteration “overprint” of the host geology when they form. Therefore, Kavango believes the IOCG model represents a second mineralisation style possibly present within the GRS, in addition to the existing potential for nickel/copper (Ni/Cu) sulphide deposits.
Kavango believes this is a significant development for the prospectivity of the GRS.
Jeremy Brett and Hillary Gumbo, Kavango’s chief geophysicists, will present the results of their work to investors in an online event on Wednesday 01 June at 1900GMT. Shareholders and investors are invited to join this event using the details below.
This event will be recorded and subsequently published on the Company’s website.
Ben Turney, Chief Executive Officer of Kavango Resources, commented:
“The IOCG target at the Great Red Spot is a significant one for Kavango Resources. We have four separate data points that appear to correspond with one another, pointing in the same direction. These include results from gravity, magnetic and Audio-MagnetoTelluric (AMT) surveys, together with magnetite encountered in Hole KSZDD001.
Given the potential size of the IOCG target and the amount of work our team has put into developing this model, we’ve decided to host an event to let our geophysicists, Jeremy Brett and Hillary Gumbo, present their work unimpeded by time constraints. Investors are welcome to join the presentation and ask questions directly.
We will also take the opportunity to present images of vertical slices taken from our AMT surveys. We’ve talked a lot over recent months about our increasingly sophisticated use of AMT and shareholders will now be able to see how important this technology could be in our attempts to open up the Kalahari Suture Zone.”
Topic: Kavango Resources Plc IOCG Presentation
Time: Jun 1, 2022 07:00 PM London
Join via
https://us02web.zoom.us/j/81288592982?pwd=OUVCTnA3M3JCemZQUTlob3QrS05zUT09
Meeting ID: 812 8859 2982
Passcode: 071048
One tap mobile
+442080806592,,81288592982#,,,,*071048# United Kingdom
+443300885830,,81288592982#,,,,*071048# United Kingdom
Dial by your location
+44 208 080 6592 United Kingdom
+44 330 088 5830 United Kingdom
+44 131 460 1196 United Kingdom
+44 203 481 5237 United Kingdom
+44 203 481 5240 United Kingdom
+44 203 901 7895 United Kingdom
+44 208 080 6591 United Kingdom
Meeting ID: 812 8859 2982
Passcode: 071048
Find your local number: https://us02web.zoom.us/u/kcEpfG5aFd
Further information in respect of the Company and its business interests is provided on the Company’s website at www.kavangoresources.com and on Twitter at #KAV.
For further information please contact:
Kavango Resources plc
Ben Turney
+46 7697 406 06
First Equity (Joint Broker)
+44 207 374 2212
Jason Robertson
SI Capital Limited (Joint Broker)
+44 1483 413500
Nick Emerson
#KDNC Cadence Minerals – Director Share Purchases
Cadence (AIM:KDNC), the mining investment company, announces that on the 8 April the following director purchased ordinary shares in the Company.
|
Director |
Position |
Number of ordinary shares acquired |
Price paid per share (£) |
|
Kiran Morzaria |
Director & CEO |
54,422 |
0.1837 |
After this acquisition and the transfer of the Employee Benefit Trust (“EBT”) shares under the 2021 share incentive scheme which vested and were announced on the 30 June 2021 and 14 January 2022 , the total notifiable share interest in the Company for the directors is as follows
|
Director |
Position |
Total holding of ordinary shares |
|
Kiran Morzaria |
Director & CEO |
1,326,422 |
|
Donald Strang |
Finance Director |
957,545 |
|
Andrew Suckling |
Non-Executive Chairman |
381,602 |
|
Adrian Fairbourn |
Non-Executive Director |
731,005 |
– Ends –
|
For further information:
|
#BVC BATM Advanced Communication – Full year Results
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces its preliminary results for the year ended 31 December 2021.
Financial Summary
|
$m |
2021 |
2020 |
Change |
|
Results from ongoing operations (adjusted)* |
|||
|
Revenue |
132.8 |
112.6 |
+1 8.0 % |
|
Gross profit |
50.2 |
41.0 |
+22.5% |
|
Gross margin |
37.8% |
36.4% |
+140bps |
|
Operating profit |
11. 3 |
2.6 |
+339.5% |
|
EBITDA |
15.7 |
6.6 |
+138.8% |
|
|
|
|
|
|
Reported results |
|||
|
Revenue |
140.0 |
183.6 |
(23.7%) |
|
Gross profit |
51.1 |
60.7 |
(15.9%) |
|
Gross margin |
36.5% |
33.1% |
+340bps |
|
Operating profit |
24. 4 |
14.2 |
+71.3% |
|
EBITDA |
29.6 |
19.7 |
+50.4% |
|
Cash from operations |
8.7 |
20.1 |
(56.8%) |
|
Basic earnings per share (cents) |
3.26¢ |
2.22¢ |
+46.8% |
|
Cash and financial assets |
67.8 |
53.4 |
+26.9% |
* Adjusted to present the results on an ongoing operations basis by excluding (1) the contribution to both years from NGSoft, a subsidiary that the Group sold in March 2021, (2) the contribution to 2020 from a significant contract for the supply of ventilators, which was exceptional in nature, and (3) the amortisation of intangible assets for both years. The term ‘ongoing operations’ in this announcement is used for comparative purposes only and is not used in the same context as in accounting standards. For further information see Note 3 – Other alternative measures.
Operational Summary
Bio-Medical Division (84% of total revenue from ongoing operations)
· Revenue from ongoing operations ( excluding the contribution to 2020 from an exceptional ventilator contract) increased by 17.7% to $112.0m (2020: $95.2m), reflecting growth in all units
· Diagnostics Unit – revenue +38%
o Significant sales growth driven by strong global demand for COVID-19 test kits (reagents) and diagnostic instruments and supported by increased sales of products in other disease areas
o Expanded COVID-19 diagnostics portfolio with launch of new solutions, including a test that uses self-collected saliva samples and the RAPiDgen® SARS-CoV-2 Ag test for at-home use
o PCR and iso-thermal method being developed by the Group for the rapid and comprehensive diagnosis of tuberculosis received the backing of the Stop TB Partnership, an international alliance
· Eco-Med Unit – revenue +37% (excl. contribution from exceptional ventilator contract)
o Returned to underlying growth with delivery resuming on contracts for the installation of the Group’s ISS-based pathogenic waste treatment solution
o Progress made in projects with Ceva Animal Health and a Taiwanese agri-food conglomerate
o Awarded a contract for its agri-waste treatment solution by a cattle facility in Botswana – the Group’s first contract for its agri-waste solution in Africa
· Distribution Unit – revenue +9%
o Increased revenue driven by the distribution of several molecular tests and of COVID-19 diagnostic reagents and equipment
Networking and Cyber Division (16% of total revenue from ongoing operations)
· Revenue from ongoing operations (which excludes the contribution from NGSoft to both years) increased by 19.5% to $20.7m (2020: $17.3m) , reflecting underlying growth in both the Networking and Cyber units
· Networking Unit – revenue +13% (excl. contribution from NGSoft)
o Launched Edgility, an ecosystem of networking products and services for edge computing based on the Group’s network function virtualisation (“NFV”) technology
§ Won two edge computing contracts expected to be worth an aggregate of $2.7m over a multi-year period, which commenced generating revenue post year end
§ Successful proof-of-concepts conducted with several potential customers and partners worldwide, which the Group expects will translate to orders in 2022
§ Established four new partnerships, including one post period, to boost Edgility sales and market presence through the offering of joint solutions
§ Expanded addressable market with enhancement of Edgility OS to enable use for public cloud environments
o Network Edge (Carrier Ethernet)
§ Resumption of normal business practices resulted in an increase in revenue during the year and a substantial increase in backlog, which is for delivery in 2022
§ Awarded a contract from a new tier 1 telecommunications operator customer in APAC, which contributed significantly to the unit’s growth
· Cyber Unit – revenue +111%
o Awarded over $18m in cyber security contracts from a long-standing government defence department customer
o Delivery of these orders commenced during the year and will continue in 2022 and 2023
o The contracts include a $10m multi-year contract for the delivery of an advanced network security solution containing elements of NFV protection
Commenting on the results, Dr Zvi Marom, Chief Executive Officer of BATM, said: “ We are delighted to be announcing another excellent set of results with growth from ongoing operations in all of our business units. We are particularly proud of the significant progress made in our Diagnostics unit, where our investment in recent years has really come to fruition, and of the substantial contracts awarded during the year in our cyber business. We were also excited to launch our Edgility platform for edge computing and virtual networking, which we believe will be a key driver of our future growth.
“Looking ahead, we entered the new year with sustained momentum across the business and we remain on track to deliver significant growth for full year 2022, in line with market expectations. We have established solid foundations in core technologies that are now at an inflexion point of becoming market disrupters. We will continue to cultivate growth and development across our business as well as pursue opportunities to accelerate the realisation of the value of the IP within our different units through strategic transactions. We have an exciting future ahead of us and we look forward to reporting on our progress and delivering value for our shareholders. “
Enquiries:
|
BATM Advanced Communications |
|
|
Dr Zvi Marom, Chief Executive Officer |
+972 9866 2525 |
|
Moti Nagar, Chief Financial Officer |
|
|
|
|
|
Shore Capital |
|
|
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory) |
+44 20 7408 4050 |
|
Henry Willcocks (Corporate Broking) |
|
|
|
|
|
Luther Pendragon |
|
|
Harry Chathli, Claire Norbury |
+44 20 7618 9100 |
#SVML Sovereign Metals – Appointment of Joint Corporate Broker
Sovereign Metals Limited (ASX:SVM; AIM:SVML) (Company or Sovereign ) is pleased to to announce the appointment of Joh. Berenberg, Gossler & Co KG (Berenberg) as the Company’s Joint Corporate Broker, for purposes of the Company’s AIM listing, with immediate effect .
Berenberg, who are based in London, will work alongside the Company’s broker Optiva Securities to further assist in raising Sovereign’s profile in UK and European capital markets.
Sovereign’s UK-based Chairman Ben Stoikovich commented : “We look forward to working with Berenberg as Sovereign continues to gain recognition amongst both retail and institutional UK and European investors as a world-class critical raw material company with sustainability and ESG at its core”
ENQUIRIES
|
Dr Julian Stephens (Perth) +61(8) 9322 6322 |
Sam Cordin (Perth) |
Sapan Ghai (London)
|
|
Nominated Adviser on AIM |
|
|
RFC Ambrian |
|
|
Bhavesh Patel / Andrew Thomson |
+44 20 3440 6800 |
|
|
|
|
Joint Brokers |
|
|
Berenberg |
+44 20 3207 7800 |
|
Matthew Armitt |
|
|
Jennifer Lee |
|
|
Varun Talwar |
|
|
|
|
|
Optiva Securities |
+44 20 3137 1902 |
|
Daniel Ingrams |
|
|
Mariela Jaho |
|
|
Christian Dennis |
#POLB Poolbeg Pharma – Artificial Intelligence deal with OneThree Biotech
Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an agreement with OneThree Biotech, Inc . a biology-driven artificial intelligence (‘AI’) company, to identify new drug targets and treatments for Respiratory Syncytial Virus (‘RSV’).
Under the terms of the transaction and as aligned with Poolbeg’s strategy, OneThree Biotech’s state-of-the-art AI analysis tools will identify drug assets which target immune-response pathways, have a higher probability of clinical success and have the potential to prevent and / or treat infectious diseases. The analysis will prioritise drugs with existing Phase I safety data, reducing spend and risk, which can feed into Poolbeg’s rapid, capital light clinical development strategy and its expanding pipeline of assets. The analysis is expected to commence in Q1 2022 with preliminary outputs from this work expected in H2 2022.
OneThree Biotech is a clinically validated AI company with a proven technology platform which integrates chemical, biological, and clinical data with cutting-edge computational tools to answer complex questions surrounding disease biology and drug discovery. The team at OneThree will work closely with Poolbeg’s scientific team to build a tailored AI analysis model which can leverage the unique insights of human challenge trial data to identify disease-relevant cell signalling pathways which could lead to novel drug targets. OneThree will receive milestone payments based on candidate development and royalties on the sale of products derived from this partnership.
The Company believe that this partnership with OneThree Biotech is the first time that AI analysis has been undertaken on RSV human challenge trial data and samples to identify new drug targets. The unique nature of human challenge trials to produce disease progression data with high precision is expected to revolutionise the insights generated from this analysis. Poolbeg’s lead asset POLB 001, which is progressing towards its first human challenge trial in June 2022, was identified using such disease progression data. However, by utilising AI the Company aims to identify more targets, quicker and more cost efficiently than previously possible without this technology.
Poolbeg entered a partnership with Eurofins Genomics in October 2021 to complete RNA sequencing of Poolbeg’s RSV disease progression samples from human challenge trials. This work was a key step in Poolbeg advancing its AI analysis programme. This RSV discovery dataset has been specifically designed for incorporation into OneThree’s AI platform. The data sets within this project will leverage up to 140Gb of biological data per subject spread over baseline healthy measurements and the course of infection which is expected to unveil unprecedented insights.
RSV is a contagious virus that affects the respiratory tract of children and at-risk older adults; in severe cases, it can cause pneumonia and other life-threatening breathing difficulties. RSV is a significant public health threat affecting an estimated 50-million people annually, leading to 4 million global hospitalisations and up to 74,500 in-hospital deaths in children under the age of 5 years. An estimated 45% of these cases and deaths occur in new-born infants under the age of 6 months.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“OneThree Biotech’s AI analysis tools will allow us to break new ground in data-driven drug discovery, by allowing us to evaluate and interrogate human challenge trial data like never before. This is a key part of our growth strategy, as we’ll be able to identify and develop drugs in a more time and cost effective manner, compared with the traditional biotech model. It will enable us to identify potential new treatments which have a higher probability of clinical success and which can feed into our rapidly expanding pipeline in-line with our capital light model.
This will be the first time that AI tools will be used to analyse RSV human challenge trial disease progression data, which illustrates the significance of this deal as well as Poolbeg’s innovative model. We look forward to updating the market on the outputs from this cutting-edge AI analysis in due course.”
Neel S. Madhukar, PhD, co-founder and CEO of OneThree Biotech , said:
“At OneThree our mission has always been to unlock new therapeutic opportunities by understanding biology on a deeper level. The ability to combine our AI platform with the data and expertise from Poolbeg Pharma will enable just that, and create an opportunity to make meaningful progress in the treatment of infectious diseases.”
Brad Pryde, co-founder and COO of OneThree Biotech , concluded:
“We have been impressed with Poolbeg Pharma’s clear dedication towards using technology and data to create efficiencies in drug discovery and development. We’re excited to demonstrate the strength of this partnership as future developments arise.”
Footnote: During a human challenge study, a number of healthy volunteers are exposed to an infectious agent in a safe and controlled quarantine setting to assess the efficacy of vaccines or treatments. Human challenge trial data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease from pre-infection, onset, progression and resolution of an infection .
– Ends –
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers , Sunila de Silva (ECM)
|
+44 (0) 20 7220 0500 |
|
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020 |
|
Little Dog Communications for OneThree Jessica Yingling, Ph.D.
|
+1 (858) 344-8091 |
Cadence Minerals #KDNC – Result of Placing & Subscription and TVR
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CADENCE MINERALS PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Cadence Minerals Plc
(“Cadence Minerals”, “Cadence” or the “Company”)
Result of Placing & Subscription and Total Voting Rights
Cadence Minerals (AIM/AQX: KDNC; OTC: KDNCY) is pleased to announce that it has successfully raised gross proceeds of £4.1 million in an oversubscribed fundraising as announced yesterday (the “Placing”).
A total of 19,512,180 Placing Shares in the Company have been placed by WH Ireland Limited (“WH Ireland”) with new and existing investors at a price of 20.5 pence per share (the “Issue Price”).
In addition, the Company has secured a further £0.1 million via a direct subscription (the “Subscription”) of 487,805 shares at the Issue Price (the “Subscription Shares”).
The fundraise was significantly oversubscribed in both the Placing and Subscription and the Directors of the Company are delighted by the support from existing shareholders and new investors, including institutional investors.
Application will be made to the London Stock Exchange for the Placing Shares and Subscription Shares to be admitted to trading on AIM and to the AQSE Growth Market and it is anticipated that dealings in the Placing and Subscription Shares will commence on AIM at 8.00 a.m. on 10 February 2022 (“Admission”). The Placing and Subscription Shares will represent approximately 11.9 per cent. of the Company’s issued share capital following completion of the Placing (“Enlarged Share Capital”). The Issue Price represents a discount of approximately 17.1 per cent. to the closing mid-market price of Cadence’s existing ordinary shares of 24.75 pence on 1 February 2022 (being the last business day prior to the announcement of the Placing yesterday).
Following Admission, the Company’s issued and fully paid share capital will consist of 168,049,083 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. The figure of 168,049,083 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Capitalised terms used but not defined in this announcement have the meanings given to them in the Company’s announcement released earlier today in respect of the Placing unless the context provides otherwise.
Enquiries:
|
Cadence Minerals plc |
+44 (0) 207 440 0647 |
|
Andrew Suckling |
|
|
Kiran Morzaria |
|
|
|
|
|
WH Ireland Limited (NOMAD & Broker) |
+44 (0) 207 220 1666 |
|
James Joyce / Darshan Patel |
|
|
Harry Ansell / Daniel Bristowe |
|
|
|
|
|
Novum Securities Limited (Joint Broker) |
+44 (0) 207 399 9400 |
|
Jon Belliss |
|
This announcement includes inside information as defined in Article 7 of the UK version of Market Abuse Regulation No. 596/2014 as it forms part of UK law as retained EU law as defined in, and by virtue of, the European Union (Withdrawal) Act 2018, as amended, and is disclosed in accordance with the Company’s obligations under Article 17 of those Regulations.
#ECHO Echo Energy – Total Voting Rights
Echo Energy, the Latin American focused full cycle energy company announces, in accordance with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, the following information as at 31 January 2022:
|
Class of share |
Total number of shares |
Number of voting rights per share |
Total number of voting rights per class of share
|
|
Ordinary shares of 0.25p each (“Ordinary Shares”)
|
1,452,491,345
|
1 |
1,452,491,345
|
No Ordinary Shares are held in treasury.
The above figure for total number of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
